Economic and Healthcare Burden in Patients with Sjögren's Syndrome: A Systematic Review
Author(s)
Kiruthika Umapathi, D.Pharm1, Raj J. Ahiwale, PhD1, Liliane Martinez, MD MSc2, Immaculate F. Nevis, MD, PhD, MBA3;
1ICON plc, Bangalore, India, 2ICON plc, Mexico City, Mexico, 3ICON plc, Lead Consultant, Fort Johnson, NY, USA
1ICON plc, Bangalore, India, 2ICON plc, Mexico City, Mexico, 3ICON plc, Lead Consultant, Fort Johnson, NY, USA
OBJECTIVES: To conduct a systematic literature review of the direct costs (DC), indirect costs (IDC) and resource utilization among patients with Sjögren's syndrome (SS).
METHODS: Literature search was conducted using Medline and EMBASE from January 2020 to August 2024. Studies included observational, post-hoc analyses of RCTs, and economic evaluations that reported costs or resource use in adults diagnosed with primary and/or secondary SS.
RESULTS: A total of 973 citations were screened, with 13 studies included. These studies were conducted across nine countries with sample sizes ranging from 12 to 32,184 individuals. One study in patients with a diagnosis of SS-associated interstitial lung disease (ILD), the DCs, were higher at USD23,192 compared to USD8,648 for patients with SS alone over a period of 180 days. In the same study, the annual medication costs varied, ranging from USD1,319 for SS controls to USD3,785 for SS-ILD patients in the U.S.; EUR501 in Italy; and SEK41,662 in Sweden. A study on primary SS reported that the mean annual total cost was USD5,748. A study conducted in US reported an average cost of USD15,656 in patients with moderate-to-severe disease. Hospitalization and outpatient care costs for newly diagnosed patients with SS were higher at SEK86,003 and SEK61,112 respectively, compared to SEK 0 and SEK7,961 for previously diagnosed SS patient. Over 180-day period, emergency visit costs were USD232 for SS-ILD cases versus USD140 for SS-only cases, as reported in one study. The mean annual IDC was USD41,094 among the overall SS population reported in one study. Sick leave affected 44-48% of patients with durations ranging from 53-67 days. Hospital stays varied between 2.6 days in a study with patients with primary SS to 13.6 days in a study with SS patients.
CONCLUSIONS: This review synthesized evidence on the costs associated with SS highlighting variations based on patient demographics and geographical regions.
METHODS: Literature search was conducted using Medline and EMBASE from January 2020 to August 2024. Studies included observational, post-hoc analyses of RCTs, and economic evaluations that reported costs or resource use in adults diagnosed with primary and/or secondary SS.
RESULTS: A total of 973 citations were screened, with 13 studies included. These studies were conducted across nine countries with sample sizes ranging from 12 to 32,184 individuals. One study in patients with a diagnosis of SS-associated interstitial lung disease (ILD), the DCs, were higher at USD23,192 compared to USD8,648 for patients with SS alone over a period of 180 days. In the same study, the annual medication costs varied, ranging from USD1,319 for SS controls to USD3,785 for SS-ILD patients in the U.S.; EUR501 in Italy; and SEK41,662 in Sweden. A study on primary SS reported that the mean annual total cost was USD5,748. A study conducted in US reported an average cost of USD15,656 in patients with moderate-to-severe disease. Hospitalization and outpatient care costs for newly diagnosed patients with SS were higher at SEK86,003 and SEK61,112 respectively, compared to SEK 0 and SEK7,961 for previously diagnosed SS patient. Over 180-day period, emergency visit costs were USD232 for SS-ILD cases versus USD140 for SS-only cases, as reported in one study. The mean annual IDC was USD41,094 among the overall SS population reported in one study. Sick leave affected 44-48% of patients with durations ranging from 53-67 days. Hospital stays varied between 2.6 days in a study with patients with primary SS to 13.6 days in a study with SS patients.
CONCLUSIONS: This review synthesized evidence on the costs associated with SS highlighting variations based on patient demographics and geographical regions.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
EE464
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies, Work & Home Productivity - Indirect Costs
Disease
SDC: Musculoskeletal Disorders (Arthritis, Bone Disorders, Osteoporosis, Other Musculoskeletal), SDC: Neurological Disorders, SDC: Rare & Orphan Diseases, SDC: Systemic Disorders/Conditions (Anesthesia, Auto-Immune Disorders (n.e.c.), Hematological Disorders (non-oncologic), Pain)